Race Oncology Ltd (ASX:RAC) executive director Pete Smith speaks with Proactive alongside the company’s recently appointed CEO - 25-year veteran of the biotech space, Dr Daniel Tillett. In this pivotal role, Dr Tillett will work closely with Dr Smith to steer the company's strategic, clinical and commercialisation efforts, with a primary focus on advancing bisantrene. Dr Tillett is already well acquainted with the cancer-targeting biotech firm. From September 2019 to March 2023, he served as Race's chief scientific officer and executive director, playing a crucial role in the company's growth and development. After this initial tenure, he continued to contribute to Race in a consultancy capacity.
“My priority in stepping in as CEO is to ensure the clinical strategy we have for bisantrene is implemented and our promise to shareholders delivered. My belief in bisantrene and its commercial potential has never wavered," Dr Tillett said. “We have an outstanding team at Race to execute on these opportunities and make a real difference for both patients and shareholders."
Contact Details
Proactive Investors
Gregg Castano
+1 203-762-5649
gregg.castano@newsdirect.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases
Race Oncology Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on improving the lives of cancer patients around the world by developing a novel approach to both treating the cancer and protecting the heart. Its lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations. It is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia.